Chimerix Stock Price, News & Analysis

Chimerix (NASDAQ:CMRX) announced promising preclinical results for CMX521 in reducing viral load and clinical symptoms in a SARS-CoV-2 mouse model. These findings will be presented at the International Conference on Antiviral Research on March 23, 2022. The study showed a >99.9% reduction in lung viral titers when CMX521 was administered prophylactically. Furthermore, the compound demonstrated a favorable safety profile in prior human trials. The company aims to advance CMX521 towards clinical proof-of-concept amid ongoing collaborations.

Chimerix (NASDAQ:CMRX) announced a live conference call scheduled for March 1, 2022, at 8:30 a.m. ET to review its financial results for Q4 and the full year ending December 31, 2021. The call will provide insights into the company’s progress alongside a business overview. Chimerix, focused on developing therapies for deadly diseases, recently gained FDA approval for TEMBEXA, a smallpox treatment, and is advancing two clinical programs: ONC201 for glioma and DSTAT for acute myeloid leukemia.

Chimerix (NASDAQ:CMRX) will have Mike Andriole, Chief Business and Financial Officer, present a corporate overview at the B. Riley Virtual Oncology Conference on January 27, 2022, at 3:00 p.m. ET. An audio webcast of the presentation will be accessible on the Investor Relations section of Chimerix's website for about 90 days following the event.

Chimerix is dedicated to developing medicines for deadly diseases, notably having received FDA approval for TEMBEXA for smallpox treatment. The company is also advancing ONC201 for recurrent glioma and DSTAT for acute myeloid leukemia.

Chimerix (NASDAQ:CMRX) announced the publication of a peer-reviewed article on its Phase 2 study of ONC201 in neuroendocrine tumors, including pheochromocytoma-paraganglioma and desmoplastic small round cell tumor. The study involved 30 patients and showed that 50% of paraganglioma patients receiving ONC201 once weekly had a partial response, with no decline in performance status for 93% of participants. This data supports further investigation into ONC201's efficacy for neuroendocrine tumors, alongside its primary focus on recurrent H3 K27M-mutant diffuse midline glioma.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced that its management team, including CEO Mike Sherman and CFO Mike Andriole, will participate in a pre-recorded fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The session will be available on January 10, 2022, at 7:00 a.m. ET. An audio webcast of the event will be accessible on their Investor Relations website for about 90 days. Chimerix focuses on developing medicines to improve patient lives, with recent FDA approval of TEMBEXA for smallpox treatment.

Chimerix (NASDAQ:CMRX) announced positive data from a 50-patient efficacy analysis of ONC201 for treating recurrent H3 K27M-mutant diffuse midline glioma. The data will be presented on November 20, 2021, during the Society for Neuro-Oncology Annual Meeting. Key highlights include a 20% overall response rate and a median duration of response of 11.2 months. The FDA has granted ONC201 several designations to expedite its development. A conference call to discuss the results is scheduled for November 22, 2021.

Chimerix (NASDAQ:CMRX) announced that CEO Mike Sherman will present at the Jefferies London Healthcare Conference on November 18, 2021, at 3:00 a.m. ET. This pre-recorded presentation will be accessible via an audio webcast on Chimerix's Investor Relations website, where it will be archived for 90 days. Chimerix focuses on developing medicines for patients with life-threatening diseases, having recently received FDA approval for TEMBEXA to treat smallpox and advancing clinical-stage programs for ONC201 and dociparstat sodium in oncology.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company, announced its data presentations at the Society for Neuro-Oncology Annual Meeting 2021 in Boston from November 19-21, 2021. The late-breaking plenary oral presentation titled "Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients" will occur on November 20, 2021. Additional presentations will cover ONC201's activity and safety in various glioma cases. Chimerix is committed to developing treatments for deadly diseases and recently received FDA approval for TEMBEXA to treat smallpox.

Chimerix (NASDAQ:CMRX) announced positive topline results from ONC201 for treating recurrent H3 K27M-mutant glioma, showing a 20% overall response rate. Additionally, the FDA published a benefit-risk assessment of TEMBEXA for smallpox. In the third quarter of 2021, Chimerix reported a net loss of $18.6 million and revenues of $0.1 million, a decline from $1.6 million the previous year. R&D expenses rose to $13.8 million, driven by an expanded pipeline following the Oncoceutics acquisition. The company has $125 million in capital to fund operations.